Medullary Thyroid Cancer

• Medullary Thyroid Cancer (MTC) is a rare neuroendocrine tumor originating from the thyroid’s C cells.
• It can be sporadic or hereditary, with hereditary forms often linked to MEN2 syndromes.
• Common symptoms include a neck lump, swollen lymph nodes, and sometimes diarrhea or flushing.
• Diagnosis involves blood tests for calcitonin and CEA, imaging, and fine needle aspiration biopsy.
• Treatment typically involves surgery, with targeted therapies or chemotherapy for advanced cases.

What is Medullary Thyroid Cancer?

Medullary Thyroid Cancer (MTC) is a distinct type of thyroid malignancy that develops from the parafollicular C cells of the thyroid gland. These C cells are responsible for producing calcitonin, a hormone involved in calcium regulation. Unlike the more common papillary and follicular thyroid cancers, MTC is considered a neuroendocrine tumor. It accounts for approximately 1-2% of all thyroid cancers.

MTC can occur sporadically (about 75% of cases) or be hereditary (about 25% of cases), often associated with inherited genetic mutations in the RET proto-oncogene, particularly in syndromes like Multiple Endocrine Neoplasia type 2 (MEN2). Early detection is crucial for effective management due to its potential for aggressive behavior and metastasis.

Symptoms and Causes of Medullary Thyroid Cancer

Medullary thyroid cancer symptoms often develop gradually and may not be immediately noticeable. The most common initial symptom is a painless lump or nodule in the neck, which may be felt by the individual or discovered during a routine physical examination. As the cancer progresses, other symptoms can emerge due to tumor growth or the overproduction of hormones by the C cells.

Common symptoms include:

• A palpable lump or swelling in the neck.
• Swollen lymph nodes in the neck.
• Difficulty swallowing (dysphagia) or breathing (dyspnea) if the tumor presses on the esophagus or trachea.
• Hoarseness or changes in voice.
• Diarrhea, which can be chronic and severe, caused by high levels of calcitonin or other hormones produced by the tumor.
• Flushing, a sudden reddening of the face and neck, also due to hormone overproduction.

The causes of medullary thyroid cancer are primarily genetic. Approximately 75% of cases are sporadic, meaning they occur without a family history and are not inherited. These sporadic cases are believed to arise from somatic mutations in the RET proto-oncogene that occur during a person’s lifetime. The remaining 25% are hereditary, linked to germline mutations in the RET proto-oncogene, which are passed down through families. Hereditary MTC is a hallmark feature of Multiple Endocrine Neoplasia type 2 (MEN2) syndromes, specifically MEN2A and MEN2B, and familial medullary thyroid cancer (FMTC). In these hereditary forms, individuals have a significantly increased risk of developing MTC, often at a younger age, and may also be predisposed to other endocrine tumors like pheochromocytoma and parathyroid hyperplasia. Genetic testing for RET mutations is vital for individuals with a family history of MTC or those diagnosed with the hereditary form to identify at-risk relatives.

Diagnosing Medullary Thyroid Cancer

The medullary thyroid cancer diagnosis process typically involves a combination of physical examination, blood tests, imaging studies, and biopsy. When a thyroid nodule is detected, the initial steps often include blood tests to measure levels of thyroid-stimulating hormone (TSH) and thyroid hormones. However, for MTC, specific tumor markers are crucial.

Key diagnostic steps include:

• Blood Tests: Elevated serum calcitonin levels are a primary indicator of MTC, as C cells produce this hormone. The level of calcitonin often correlates with tumor burden. Elevated Carcinoembryonic Antigen (CEA) levels can also be present in MTC and are often used in conjunction with calcitonin for diagnosis and monitoring. Genetic testing for mutations in the RET proto-oncogene is essential, especially if MTC is suspected to be hereditary or if there’s a family history.
• Imaging Studies: Ultrasound of the neck is typically the first imaging test to characterize thyroid nodules and assess for suspicious features and enlarged lymph nodes. CT or MRI scans may be used to evaluate the extent of the disease, check for spread to lymph nodes in the chest, or distant metastases. PET scans are sometimes used in advanced cases to detect metastatic disease.
• Fine Needle Aspiration (FNA) Biopsy: A biopsy of the thyroid nodule is performed to obtain cells for pathological examination. While cytology can suggest MTC, immunohistochemical staining for calcitonin and CEA on the biopsy specimen provides a definitive diagnosis.

According to the American Cancer Society, MTC is rare, accounting for about 1% to 2% of all thyroid cancers, with approximately 500-1000 new cases diagnosed in the United States each year. (Source: American Cancer Society, “What Is Medullary Thyroid Cancer?”, accessed 2024). This rarity underscores the importance of specialized diagnostic approaches.